BioMarin (NASDAQ:BMRN): Wedbush Keeps “Buy” Rating Today, Has a Target of $112.0000/Share

May 17, 2018 - By Robert Crowder

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Logo

Investors sentiment increased to 1.21 in 2017 Q4. Its up 0.08, from 1.13 in 2017Q3. It increased, as 37 investors sold BioMarin Pharmaceutical Inc. shares while 112 reduced holdings. 51 funds opened positions while 130 raised stakes. 172.01 million shares or 0.29% more from 171.51 million shares in 2017Q3 were reported.

Toth Financial Advisory owns 400 shares for 0.01% of their portfolio. Glg Limited holds 0.05% or 7,647 shares in its portfolio. Stanley owns 64,933 shares or 1.25% of their US portfolio. Marshall Wace Llp holds 5,397 shares or 0.02% of its portfolio. Canada Pension Plan Board has 0.02% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 98,249 shares. Altrinsic Glob Advsr Limited Liability Company holds 0.19% or 56,168 shares. Hightower Advsrs Limited Liability Company reported 3,793 shares. Caisse De Depot Et Placement Du Quebec owns 2,800 shares. Hsbc Hldg Public Limited Company accumulated 39,242 shares or 0.01% of the stock. Susquehanna Gp Llp has invested 0.01% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Deutsche Bancshares Ag accumulated 1.03 million shares or 0.06% of the stock. 1.19 million are owned by Venbio Select Advisor Limited Liability Corporation. 10.25 million are held by Primecap Management Ca. Employees Retirement Systems Of Ohio holds 0.05% or 106,788 shares. Thomas J Herzfeld Advisors Incorporated stated it has 211 shares or 0.01% of all its holdings.

Since December 14, 2017, it had 0 insider purchases, and 23 sales for $18.49 million activity. Another trade for 3,750 shares valued at $333,150 was made by LAWLIS V BRYAN on Tuesday, January 2. BIENAIME JEAN JACQUES had sold 10,000 shares worth $846,285. FUCHS HENRY J had sold 10,000 shares worth $801,200 on Monday, April 2. 11,059 shares were sold by SPIEGELMAN DANIEL K, worth $908,497 on Monday, April 23. Ajer Jeffrey Robert had sold 2,972 shares worth $244,863 on Friday, March 9. The insider Mueller Brian sold $219,275.

BioMarin (NASDAQ:BMRN) Rating Reaffirmed

They currently have a $112.0000 target price on BioMarin (NASDAQ:BMRN). The target price by Wedbush would suggest a potential upside of 26.65 % from the company’s last stock close price. This has been revealed in a research report on 15 May.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Among 13 analysts covering Biomarin Pharmaceutical (NASDAQ:BMRN), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. Biomarin Pharmaceutical has $14500 highest and $9200 lowest target. $114.77’s average target is 29.79% above currents $88.43 stock price. Biomarin Pharmaceutical had 18 analyst reports since December 14, 2017 according to SRatingsIntel. The rating was maintained by Leerink Swann with “Outperform” on Friday, February 23. Deutsche Bank maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Friday, February 23 with “Buy” rating. The rating was maintained by Morgan Stanley on Monday, April 30 with “Overweight”. RBC Capital Markets maintained the shares of BMRN in report on Tuesday, February 27 with “Hold” rating. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Buy” rating by Piper Jaffray on Thursday, January 18. Wedbush maintained the shares of BMRN in report on Wednesday, December 20 with “Buy” rating. The rating was maintained by BMO Capital Markets with “Outperform” on Friday, February 23. As per Thursday, April 26, the company rating was maintained by J.P. Morgan. Stifel Nicolaus maintained the shares of BMRN in report on Friday, February 23 with “Buy” rating. As per Wednesday, January 24, the company rating was maintained by JP Morgan.

The stock decreased 1.22% or $1.09 during the last trading session, reaching $88.43. About 715,347 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 11.55% since May 18, 2017 and is downtrending. It has underperformed by 23.10% the S&P500.

Analysts await BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to report earnings on August, 1. They expect $-0.05 EPS, 0.00 % or $0.00 from last year’s $-0.05 per share. After $-0.08 actual EPS reported by BioMarin Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts -37.50 % EPS growth.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company has market cap of $15.63 billion. The Company’s commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria , an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. It currently has negative earnings. The firm also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.

More notable recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: which released: “Premarket analyst action – healthcare” on May 16, 2018, also with their article: “Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics ‘gaming’ list” published on May 17, 2018, published: “BioMarin Pharmaceutical (BMRN) Q1 2018 Results – Earnings Call Transcript” on April 26, 2018. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were released by: and their article: “BioMarin Pharma (BMRN) Reports First Patient Dosed in Phase 1/2 Study Evaluating Valoctocogene Roxaparvovec …” published on May 15, 2018 as well as‘s news article titled: “Sangamo Therapeutics Stock History” with publication date: May 17, 2018.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.